Creyos (formerly Cambridge Brain Sciences)’s Post

🌍 July is Minority Mental Health Month. Many people from racial and ethnic minority groups face significant barriers to accessing mental health care, including stigma, affordability, and provider shortages. This disparity can lead to untreated mental health issues and poorer overall health outcomes. 🌍 Creyos is committed to boosting health for cognitive and mental health care through: - offering data-driven tools for improved access to culturally-agnostic, objective cognitive testing - increased abilities to screen for mental health conditions in a primary care setting - enabling providers to perform in-depth cognitive health assessments to support referrals to a specialist Learn more about health equity challenges and solutions here ➡️https://hubs.li/Q02FbGTd0.

📝 The GUIDE CMS Model pilot emphasizes the importance of cognitive care planning for the dementia population by testing an alternative payment system for participants that deliver this service. Cognitive care planning includes an assessment of cognition and a complete written care plan. ⏱️ The Creyos platform offers a tool that fulfills the reimbursement requirements for CPT code 99483 for Cogntive Care Planning and aims to reduce the time required to write a care plan to 15 minutes. For organizations participating in GUIDE and/or offering cognitive care planning, read more on how the Creyos platform operationalizes these visits here: https://hubs.li/Q02F6xV00.

Neurocognitive testing holds tremendous potential, particularly with the increasing prevelance of cognitive and behavioral health issues. Worldwide, it's estimated 1 in every 8 individuals is living with a mental health disorder, and by 2050 it's projected nearly 139 million people will be living with dementia. However, the time-consuming and highly specialized nature of neurocognitive testing poses significant challenges to patient access. This article from the Creyos blog explores the critical role of cognitive testing, current challenges, and how Creyos addresses these issues. Through highly validated technology, Creyos enables providers to gain crucial insights into patients’ cognition, bypassing long referral times and facilitating timely treatments. Read all about it here: https://hubs.li/Q02DsJT50

The 8-year GUIDE Model pilot launches on July 1st. It's aim is to change dementia care with its comprehensive approach -- improving the lives of both those living with dementia and their caregivers. But its success hinges on one critical factor: timely and accurate dementia diagnosis. 🔍 Since early detection is key to effective intervention and better patient outcomes, imagine the impact if every provider had access to sensitive screening tools and objective diagnostic assessments. If there was a way to rapidly and reliably assess patients for signs of dementia often missed by traditional tests like the MoCA, MMSE, or Mini-Cog. With a data-backed screener and dementia assessment aligned to DSM-5 criteria, Creyos is uniquely positioned to help healthcare providers with better detection and care aligned to GUIDE. You can learn more about the GUIDE model here: https://hubs.li/Q02DsRZ_0, and if your practice is participating in GUIDE, determine for yourself whether you have the right tools to best support this new model.

Yukon Neurology transformed their cognitive evaluative process with Creyos to facilitate sensitive detection of impairments, specific identification of the impaired domain, and quantification of changes over time. Whereas traditional pen-and-paper assessments like the MoCA or the MMSE produce only a single score, having objective insights into different cognitive areas has allowed the Yukon Neurology providers to differentiate between conditions with overlapping symptoms such as dementia, anxiety, depression, and/or ADHD. Read our case study with Yukon Neurology’s Medical Director, Melissa Picchione, to discover how Creyos enabled the practice to “get to the root of the problem.” ➡️ https://hubs.li/Q02D2sNw0.

🧠 Early detection of cognitive decline is significiant in improving clinical outcomes. But what can be done to prevent decline before the point of detection? Although some factors are outside of our control, learn about the modifiable dementia risk factors and mitigation strategies to stay healthy longer in the article below: Read here: https://hubs.li/Q02CrHPc0

📈 Yukon Neurology's use of Creyos Health's cognitive assessments boasts an impressive 99% completion rate! High patient participation not only improves engagement, but also ensures accurate and timely detection, leading to better clinical outcomes.This case study highlights their success in streamlining their cognitive assessment workflow, while also prioritizing the patient experience. Learn more about their approach and results: https://hubs.li/Q02CrGBq0

The Centers for Medicare & Medicaid Services (CMS) GUIDE Model launches in just a couple of weeks on July 1st 2024. The initiative aims to enhance dementia care quality. The GUIDE Model will use an alternative payment method for participants who perform services for people with dementia, including assessments and care planning. CMS places an emphasis on the importance of quality dementia care management through incentives, but we also need to align the standard of care to include more sensitive assessment tools. By integrating these tools, we can improve clinical outcomes and ensure that patients receive the best possible care from the earliest stages of disease. 📖 Read more about the GUIDE Model initiative and how it aligns with the Comprehensive Care for Alzheimer's Act at the Alzheimer's Assocation: https://hubs.li/Q02C5hRH0

📊 Discover how Yukon Neurology transformed cognitive care with Creyos! 📊 Our latest case study highlights the incredible success of Yukon Neurology in enhancing patient outcomes through innovative cognitive assessment tools. Learn how they improved diagnostic accuracy, streamlined workflows, and delivered exceptional care. Read the full case study here: https://hubs.li/Q02BmZGx0.